Patent · US Active

Serine/threonine kinase inhibitors

US9133187B2 · kind B2 · utility

6Cited by

1References

20Claims

0Family size

Assignees

Array BioPharma, Inc. · US
Genentech, Inc. · US

Inventors

James F. Blake · Longmont, US
Huifen Chen · Burlingame, US
Mark Joseph Chicarelli · Boulder, US
Jason Demeese · Boulder, US
Rustam Ferdinand Garrey · Boulder, US
John Gaudino · Longmont, US
Robert J. Kaus · Longmont, US
Gabrielle R. Kolakowski · Boulder, US
Allison L. Marlow · Boulder, US
Peter Mohr · Basel, CH
Li Ren · Superior, US
Jacob Bradley Schwarz · San Ramon, US
Christopher Stephen Siedem · Boulder, US
Allen A. Thomas · Carlsbad, US
Eli M. Wallace · Richardson, US
Steven Mark Wenglowsky · Boulder, US
Steven A. Boyd · Longmont, US

Key dates

Filing date	Feb 28, 2012
Grant date	Sep 15, 2015
Priority date	—
Expiry date	Feb 28, 2032

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D491/052
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Compounds having the formula I wherein Z, Z1 Z2 Z3, R3a, R3b and Rb and as defined herein are inhibitors of ERK kinase. Also disclosed are compositions and methods for treating hyperproliferative disorders.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.